Head-to-head study of [18F]FAPI-04 PET/CT and [18F]FDG PET/CT for non-invasive assessment of liver cancer and its immunohistochemical markers DOI Creative Commons

Zhiying Liang,

Hao Peng, Wei Li

et al.

BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)

Published: Nov. 11, 2024

To compare the performance of [18F]FDG and [18F]FAPI-04 in PET/CT evaluation for liver cancer lesions, with a further exploration associations between PET semiquantitative data immunohistochemical markers to cancer. Patients suspected malignant lesions (MLL) underwent scanning. Liver were visually classified as positive or negative based on their uptake level exceeding that adjacent normal tissue. SUVmax tumor-to-background ratio (TBR) recorded semi-quantitative analysis. Sensitivity, specificity accuracy each tracer determined using pathological findings gold standard. Furthermore, analysis provided molecular characteristics all MLLs. Comprehensive explored correlations these parameters (SUVmax andTBR) identify potential associations. The study enrolled 44 patients, 39 confirmed cases MLL, comprising 28 hepatocellular carcinomas (HCC) 11 intrahepatic cholangiocarcinomas (ICC). For MLL detection, exhibited sensitivities 84.6% (33/39) 76.9% (30/39), specificitiesy 60% (3/5) 100%(5/5), 81.8% (36/44) 79.5%(35/44). Across significantly surpassed SUVmax(10.54 ± 6.72 VS. 7.68 6.79) TBR(4.35 3.78 Vs. 3.17 3.05). Notably, displayed markebly elevated benign (BLLs) (P = 0.032), HCCs 0.005), ICCs 0.011). Lesions hepatocyte negativity 0.023), CD34 negativity(P 0.044), high Ki67 expression (> 30%) 0.001) had higher [18F]FAPI-04. Additionally, ARG-1-negative demonstrated TBR than ARG-1-positive lesions(P 0.018). No significant SUVmax/TBR differences observed markers. A linear relationship was identified scores (R 0.603, P < 0.001). exhibits superior over cancer, characterized by increased sensitivity SUVmax/TBR. Significant markers, including Ki67, suggest [18F]FAPI-04's characterizing subtypes assessing tumor proliferation. However, research is required validate clinical significance. NCT05485792, Registered 01 August 2022.

Language: Английский

Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics DOI Creative Commons
William Serumula,

Venesen Pillay,

Bawinile Hadebe

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(4), P. 522 - 522

Published: April 3, 2025

Fibroblast activation protein (FAP) is a serine protease selectively expressed in cancer-associated fibroblasts (CAFs), fibrotic tissues, and areas of active tissue remodeling, making it an attractive target for diagnostic imaging across spectrum disease. FAP inhibitors (FAPIs) labeled with PET tracers have rapidly advanced as novel modality broad clinical applications that offers several advantages, including rapid tumor accumulation, low background uptake, high tumor-to-background ratios. In oncology, FAPI has demonstrated excellent performance visualizing wide range malignancies, those glycolytic activity, such pancreatic cancer, cholangiocarcinoma, certain sarcomas. Its sensitivity specificity the stromal component enables improved delineation, staging, response assessment. Additionally, potential to guide theranostic approaches, where same tracer can be therapeutic radionuclides, positions key player precision oncology. Beyond shown promise conditions characterized by inflammatory processes. cardiovascular field, being investigated its ability detect myocardial fibrosis cardiac crucial like heart failure, post-myocardial infarction hypertrophic cardiomyopathy. This review highlights expanding FAPI-based inflammation, While current data are promising, further large-scale studies multicenter trials essential validate these findings establish standardized protocols. The versatility applicability underscore transformative tool medicine.

Language: Английский

Citations

0
Head-to-head study of [18F]FAPI-04 PET/CT and [18F]FDG PET/CT for non-invasive assessment of liver cancer and its immunohistochemical markers DOI Creative Commons

Zhiying Liang,

Hao Peng, Wei Li

et al.

BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)

Published: Nov. 11, 2024

To compare the performance of [18F]FDG and [18F]FAPI-04 in PET/CT evaluation for liver cancer lesions, with a further exploration associations between PET semiquantitative data immunohistochemical markers to cancer. Patients suspected malignant lesions (MLL) underwent scanning. Liver were visually classified as positive or negative based on their uptake level exceeding that adjacent normal tissue. SUVmax tumor-to-background ratio (TBR) recorded semi-quantitative analysis. Sensitivity, specificity accuracy each tracer determined using pathological findings gold standard. Furthermore, analysis provided molecular characteristics all MLLs. Comprehensive explored correlations these parameters (SUVmax andTBR) identify potential associations. The study enrolled 44 patients, 39 confirmed cases MLL, comprising 28 hepatocellular carcinomas (HCC) 11 intrahepatic cholangiocarcinomas (ICC). For MLL detection, exhibited sensitivities 84.6% (33/39) 76.9% (30/39), specificitiesy 60% (3/5) 100%(5/5), 81.8% (36/44) 79.5%(35/44). Across significantly surpassed SUVmax(10.54 ± 6.72 VS. 7.68 6.79) TBR(4.35 3.78 Vs. 3.17 3.05). Notably, displayed markebly elevated benign (BLLs) (P = 0.032), HCCs 0.005), ICCs 0.011). Lesions hepatocyte negativity 0.023), CD34 negativity(P 0.044), high Ki67 expression (> 30%) 0.001) had higher [18F]FAPI-04. Additionally, ARG-1-negative demonstrated TBR than ARG-1-positive lesions(P 0.018). No significant SUVmax/TBR differences observed markers. A linear relationship was identified scores (R 0.603, P < 0.001). exhibits superior over cancer, characterized by increased sensitivity SUVmax/TBR. Significant markers, including Ki67, suggest [18F]FAPI-04's characterizing subtypes assessing tumor proliferation. However, research is required validate clinical significance. NCT05485792, Registered 01 August 2022.

Language: Английский

Citations

1